Prostate cancer vaccine - IDEC
Latest Information Update: 09 Jan 2008
At a glance
- Originator IDEC Pharmaceuticals
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 09 May 2000 Preclinical development for Prostate cancer in USA (Unknown route)